Meeting
2011 ASCO Annual Meeting
Phase I study of clofarabine and liposomal daunorubicin in childhood acute myeloid leukemia.
Authors
P. Kearns
University of Birmingham, Birmingham, United Kingdom
P. Kearns , N. J. Graham , M. Cummins , B. Gibson , J. D. Grainger , R. Keenan , D. Lancaster , G. Shenton , J. Vormoor , D. Webb , I. Hawley , P. J. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
29644734
Citation
J Clin Oncol 29: 2011 (suppl; abstr 9521)
Abstract #
9521
Poster Bd #
36B
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2019 ASCO Annual Meeting
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.
First Author: Jessica Hochberg
Poster
2023 ASCO Annual Meeting
Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.
First Author: Samer Ali Srour
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk